{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T23:56:26Z","timestamp":1794959786533,"version":"4.9.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T00:00:00Z","timestamp":1641168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T00:00:00Z","timestamp":1641168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Drug resistance to sorafenib greatly limited the benefits of treatment in patients with hepatocellular carcinoma (HCC). MicroRNAs (miRNAs) participate in the development of drug resistance. The key miRNA regulators related to the clinical outcome of sorafenib treatment and their molecular mechanisms remain to be identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The clinical significance of miRNA-related epigenetic changes in sorafenib-resistant HCC was evaluated by analyzing publicly available databases and in-house human HCC tissues. The biological functions of miR-23a-3p were investigated both in vitro and in vivo. Proteomics and bioinformatics analyses were conducted to identify the mechanisms that regulating miR-23a-3p. Luciferase reporter assay and chromatin immunoprecipitation (ChIP) assay were used to validate the binding relationship of miR-23a-3p and its targets.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We found that miR-23a-3p was the most prominent miRNA in HCC, which was overexpressed in sorafenib non-responders and indicated poor survival and HCC relapse. Sorafenib-resistant cells exhibited increased miR-23a-3p transcription in an ETS Proto-Oncogene 1 (ETS1)-dependent manner. CRISPR-Cas9 knockout of miR-23a-3p improved sorafenib response in HCC cells as well as orthotopic HCC tumours. Proteomics analysis suggested that sorafenib-induced ferroptosis was the key pathway suppressed by miR-23a-3p with reduced cellular iron accumulation and lipid peroxidation. MiR-23a-3p directly targeted the 3\u2032-untranslated regions (UTR) of ACSL4, the key positive regulator of ferroptosis. The miR-23a-3p inhibitor rescued ACSL4 expression and induced ferrotoptic cell death in sorafenib-treated HCC cells. The co-delivery of ACSL4 siRNA and miR-23a-3p inhibitor abolished sorafenib response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study demonstrates that ETS1\/miR-23a-3p\/ACSL4 axis contributes to sorafenib resistance in HCC through regulating ferroptosis. Our findings suggest that miR-23a-3p could be a potential target to improve sorafenib responsiveness in HCC patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-021-02208-x","type":"journal-article","created":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T02:03:20Z","timestamp":1641175400000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":198,"title":["Epigenetic regulation of ferroptosis via ETS1\/miR-23a-3p\/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma"],"prefix":"10.1186","volume":"41","author":[{"given":"Yuanjun","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yau-Tuen","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hor-Yue","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,3]]},"reference":[{"issue":"1","key":"2208_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"15","key":"2208_CR2","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"Villanueva A. Hepatocellular Carcinoma. N Engl J Med. 2019;380(15):1450\u201362.","journal-title":"N Engl J Med"},{"issue":"4","key":"2208_CR3","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378\u201390.","journal-title":"N Engl J Med"},{"issue":"1","key":"2208_CR4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41392-020-0187-x","volume":"5","author":"W Tang","year":"2020","unstructured":"Tang W, Chen Z, Zhang W, Cheng Y, Zhang B, Wu F, et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther. 2020;5(1):87.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2208_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","volume":"5","author":"W Tang","year":"2020","unstructured":"Tang W, Chen Z, Zhang W, Cheng Y, Zhang B, Wu F, et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther. 2020;5(1):1\u201315.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"2208_CR6","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.3390\/cancers12061576","volume":"12","author":"LKD Cabral","year":"2020","unstructured":"Cabral LKD, Tiribelli C, Sukowati CH. Sorafenib resistance in hepatocellular carcinoma: the relevance of genetic heterogeneity. Cancers. 2020;12(6):1576.","journal-title":"Cancers"},{"issue":"3","key":"2208_CR7","doi-asserted-by":"publisher","first-page":"228","DOI":"10.2174\/1574892815666200630102344","volume":"15","author":"X Xu","year":"2020","unstructured":"Xu X, Yao L. Recent patents on the development of c-met kinase inhibitors. Recent Pat Anticancer Drug Discov. 2020;15(3):228\u201338.","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"2208_CR8","doi-asserted-by":"crossref","unstructured":"Chen X, Kang R, Kroemer G, Tang D. Broadening horizons: the role of ferroptosis in cancer.\u00a0Nat Rev Clin Oncol. 2021;18(5):280\u201396.","DOI":"10.1038\/s41571-020-00462-0"},{"issue":"1","key":"2208_CR9","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12943-019-1086-z","volume":"18","author":"L Wei","year":"2019","unstructured":"Wei L, Wang X, Lv L, Liu J, Xing H, Song Y, et al. The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma. Mol Cancer. 2019;18(1):147.","journal-title":"Mol Cancer"},{"issue":"4","key":"2208_CR10","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.3892\/ijo.2014.2577","volume":"45","author":"K Liu","year":"2014","unstructured":"Liu K, Liu S, Zhang W, Ji B, Wang Y, Liu Y. miR-222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma. Int J Oncol. 2014;45(4):1537\u201346.","journal-title":"Int J Oncol"},{"issue":"19","key":"2208_CR11","first-page":"8834","volume":"10","author":"Z Lin","year":"2020","unstructured":"Lin Z, Xia S, Liang Y, Ji L, Pan Y, Jiang S, et al. LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription. #N\/A. 2020;10(19):8834.","journal-title":"#N\/A"},{"issue":"2","key":"2208_CR12","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.3892\/or.2015.4030","volume":"34","author":"K Liu","year":"2015","unstructured":"Liu K, Liu S, Zhang W, Jia B, Tan L, Jin Z, et al. miR-494 promotes cell proliferation, migration and invasion, and increased sorafenib resistance in hepatocellular carcinoma by targeting PTEN. Oncol Rep. 2015;34(2):1003\u201310.","journal-title":"Oncol Rep"},{"key":"2208_CR13","doi-asserted-by":"crossref","unstructured":"Ohta K, Hoshino H, Wang J, Ono S, Iida Y, Hata K, et al. MicroRNA-93 activates c-Met\/PI3K\/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A.\u00a0Oncotarget.\u00a02015;6(5):3211.","DOI":"10.18632\/oncotarget.3085"},{"issue":"5","key":"2208_CR14","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.jhep.2009.12.024","volume":"52","author":"S Shimizu","year":"2010","unstructured":"Shimizu S, Takehara T, Hikita H, Kodama T, Miyagi T, Hosui A, et al. The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. J Hepatol. 2010;52(5):698\u2013704.","journal-title":"J Hepatol"},{"issue":"3","key":"2208_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-018-0344-0","volume":"9","author":"K Zhang","year":"2018","unstructured":"Zhang K, Chen J, Zhou H, Chen Y, Zhi Y, Zhang B, et al. 1\/microRNA-142-3p targets ATG5\/ATG16L1 to inactivate autophagy and sensitize hepatocellular carcinoma cells to sorafenib. Cell Death Dis. 2018;9(3):1\u201316.","journal-title":"Cell Death Dis"},{"issue":"1","key":"2208_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.7785\/tcrt.2012.500364","volume":"13","author":"F Yang","year":"2014","unstructured":"Yang F, Li Q-j, Gong Z-b, Zhou L, You N, Wang S, et al. MicroRNA-34a targets Bcl-2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment. Technol Cancer Res Treat. 2014;13(1):77\u201386.","journal-title":"Technol Cancer Res Treat"},{"issue":"7","key":"2208_CR17","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1136\/gutjnl-2019-318830","volume":"69","author":"W-P Xu","year":"2020","unstructured":"Xu W-P, Liu J-P, Feng J-F, Zhu C-P, Yang Y, Zhou W-P, et al. miR-541 potentiates the response of human hepatocellular carcinoma to sorafenib treatment by inhibiting autophagy. Gut. 2020;69(7):1309\u201321.","journal-title":"Gut"},{"issue":"2","key":"2208_CR18","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.canlet.2015.11.034","volume":"371","author":"Y Xu","year":"2016","unstructured":"Xu Y, Huang J, Ma L, Shan J, Shen J, Yang Z, et al. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS\/RAF\/ERK signaling pathways. Cancer Lett. 2016;371(2):171\u201381.","journal-title":"Cancer Lett"},{"issue":"7","key":"2208_CR19","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1002\/jcp.25744","volume":"232","author":"N Potenza","year":"2017","unstructured":"Potenza N, Mosca N, Zappavigna S, Castiello F, Panella M, Ferri C, et al. MicroRNA-125a-5p is a downstream effector of sorafenib in its antiproliferative activity toward human hepatocellular carcinoma cells. J Cell Physiol. 2017;232(7):1907\u201313.","journal-title":"J Cell Physiol"},{"issue":"9","key":"2208_CR20","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1111\/cas.13006","volume":"107","author":"J Azumi","year":"2016","unstructured":"Azumi J, Tsubota T, Sakabe T, Shiota G. miR-181a induces sorafenib resistance of hepatocellular carcinoma cells through downregulation of RASSF 1 expression. Cancer Sci. 2016;107(9):1256\u201362.","journal-title":"Cancer Sci"},{"issue":"4","key":"2208_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-020-2413-4","volume":"11","author":"L Ji","year":"2020","unstructured":"Ji L, Lin Z, Wan Z, Xia S, Jiang S, Cen D, et al. miR-486-3p mediates hepatocellular carcinoma sorafenib resistance by targeting FGFR4 and EGFR. Cell Death Dis. 2020;11(4):1\u201315.","journal-title":"Cell Death Dis"},{"key":"2208_CR22","doi-asserted-by":"crossref","unstructured":"Sempere LF, Preis M, Yezefski T, Ouyang H, Suriawinata AA, Silahtaroglu A, et al. Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered MicroRNA expression in solid tumors.\u00a0Clin Cancer Res.\u00a02010;16(16):4246\u201355.","DOI":"10.1158\/1078-0432.CCR-10-1152"},{"key":"2208_CR23","doi-asserted-by":"crossref","unstructured":"Apicella M, Giannoni E, Fiore S, Ferrari KJ, Fern\u00e1ndez-P\u00e9rez D, Isella C, et al. Comoglio PMJCm: Increased lactate secretion by cancer cells sustains non-cell-autonomous adaptive resistance to MET and EGFR targeted therapies. 2018;28(6):848\u201365 e846.","DOI":"10.1016\/j.cmet.2018.08.006"},{"issue":"11","key":"2208_CR24","doi-asserted-by":"publisher","first-page":"8463","DOI":"10.1128\/JVI.72.11.8463-8471.1998","volume":"72","author":"T Dull","year":"1998","unstructured":"Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol. 1998;72(11):8463\u201371.","journal-title":"J Virol"},{"issue":"4","key":"2208_CR25","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1261\/rna.2192803","volume":"9","author":"SA Stewart","year":"2003","unstructured":"Stewart SA, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, An DS, et al. Lentivirus-delivered stable gene silencing by RNAi in primary cells. Rna. 2003;9(4):493\u2013501.","journal-title":"Rna"},{"issue":"20","key":"2208_CR26","doi-asserted-by":"publisher","first-page":"4051","DOI":"10.1038\/sj.emboj.7600385","volume":"23","author":"Y Lee","year":"2004","unstructured":"Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 2004;23(20):4051\u201360.","journal-title":"EMBO J"},{"issue":"9","key":"2208_CR27","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.bbagrm.2014.05.027","volume":"1839","author":"N Wang","year":"2014","unstructured":"Wang N, Zhu M, Wang X, Tan H-Y, Tsao S-w, Feng Y. Berberine-induced tumor suppressor p53 up-regulation gets involved in the regulatory network of MIR-23a in hepatocellular carcinoma. Biochim Biophys Acta. 2014;1839(9):849\u201357.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"2208_CR28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12943-019-0992-4","volume":"18","author":"Y Qu","year":"2019","unstructured":"Qu Y, Dou B, Tan H, Feng Y, Wang N, Wang D. Tumor microenvironment-driven non-cell-autonomous resistance to antineoplastic treatment. Mol Cancer. 2019;18(1):69.","journal-title":"Mol Cancer"},{"issue":"46","key":"2208_CR29","doi-asserted-by":"publisher","first-page":"19879","DOI":"10.1073\/pnas.1007698107","volume":"107","author":"MQ Hassan","year":"2010","unstructured":"Hassan MQ, Gordon JA, Beloti MM, Croce CM, Van Wijnen AJ, Stein JL, et al. A network connecting Runx2, SATB2, and the miR-23a\u223c 27a\u223c 24-2 cluster regulates the osteoblast differentiation program. Proc Natl Acad Sci. 2010;107(46):19879\u201384.","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"2208_CR30","first-page":"1","volume":"8","author":"H Huang","year":"2018","unstructured":"Huang H, Liu Y, Yu P, Qu J, Guo Y, Li W, et al. MiR-23a transcriptional activated by Runx2 increases metastatic potential of mouse hepatoma cell via directly targeting Mgat3. Sci Rep. 2018;8(1):1\u201311.","journal-title":"Sci Rep"},{"issue":"11","key":"2208_CR31","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1002\/mc.22698","volume":"56","author":"LE Mullany","year":"2017","unstructured":"Mullany LE, Herrick JS, Wolff RK, Stevens JR, Samowitz W, Slattery ML. Transcription factor-microRNA associations and their impact on colorectal cancer survival. Mol Carcinog. 2017;56(11):2512\u201326.","journal-title":"Mol Carcinog"},{"key":"2208_CR32","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.phrs.2018.08.003","volume":"135","author":"Z Shao","year":"2018","unstructured":"Shao Z, Li Y, Dai W, Jia H, Zhang Y, Jiang Q, et al. ETS-1 induces Sorafenib-resistance in hepatocellular carcinoma cells via regulating transcription factor activity of PXR. Pharmacol Res. 2018;135:188\u2013200.","journal-title":"Pharmacol Res"},{"issue":"1","key":"2208_CR33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13045-019-0720-y","volume":"12","author":"Y Mou","year":"2019","unstructured":"Mou Y, Wang J, Wu J, He D, Zhang C, Duan C, et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J Hematol Oncol. 2019;12(1):34.","journal-title":"J Hematol Oncol"},{"key":"2208_CR34","doi-asserted-by":"crossref","unstructured":"Dixon SJ, Patel DN, Welsch M, Skouta R, Lee ED, Hayano M, et al. Pharmacological inhibition of cystine\u2013glutamate exchange induces endoplasmic reticulum stress and ferroptosis.\u00a0Elife.\u00a02014;3:e02523.","DOI":"10.7554\/eLife.02523"},{"issue":"1","key":"2208_CR35","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/cancers11010007","volume":"11","author":"N Wang","year":"2019","unstructured":"Wang N, Tan H-Y, Feng Y-G, Zhang C, Chen F, Feng Y. microRNA-23a in human cancer: its roles, mechanisms and therapeutic relevance. Cancers. 2019;11(1):7.","journal-title":"Cancers"},{"issue":"1","key":"2208_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-4598-12-119","volume":"12","author":"N Wang","year":"2013","unstructured":"Wang N, Zhu M, Tsao S-W, Man K, Zhang Z, Feng Y. MiR-23a-mediated inhibition of topoisomerase 1 expression potentiates cell response to etoposide in human hepatocellular carcinoma. Mol Cancer. 2013;12(1):1\u201310.","journal-title":"Mol Cancer"},{"key":"2208_CR37","doi-asserted-by":"crossref","unstructured":"Tang D, Chen X, Kang R, Kroemer G. Ferroptosis: molecular mechanisms and health implications. Cell Res. 2021;31(2):107\u201325.","DOI":"10.1038\/s41422-020-00441-1"},{"issue":"2","key":"2208_CR38","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2174\/1574892814666190514104035","volume":"14","author":"E Ekinci","year":"2019","unstructured":"Ekinci E, Rohondia S, Khan R, Dou QP. Repurposing Disulfiram as An anti-Cancer agent: updated review on literature and patents. Recent Pat Anticancer Drug Discov. 2019;14(2):113\u201332.","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"2208_CR39","doi-asserted-by":"crossref","unstructured":"Conrad M, Lorenz SM, Proneth B. Targeting Ferroptosis: new Hope for as-yet-incurable diseases. Trends Mol Med.\u00a02021;27(2):113\u201322.","DOI":"10.1016\/j.molmed.2020.08.010"},{"key":"2208_CR40","doi-asserted-by":"publisher","first-page":"571127","DOI":"10.3389\/fonc.2020.571127","volume":"10","author":"Y Wu","year":"2020","unstructured":"Wu Y, Yu C, Luo M, Cen C, Qiu J, Zhang S, et al. Ferroptosis in cancer treatment: another way to Rome. Front Oncol. 2020;10:571127.","journal-title":"Front Oncol"},{"issue":"1","key":"2208_CR41","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/hep.28251","volume":"63","author":"X Sun","year":"2016","unstructured":"Sun X, Ou Z, Chen R, Niu X, Chen D, Kang R, et al. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology. 2016;63(1):173\u201384.","journal-title":"Hepatology"},{"issue":"7","key":"2208_CR42","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1002\/ijc.28159","volume":"133","author":"C Louandre","year":"2013","unstructured":"Louandre C, Ezzoukhry Z, Godin C, Barbare JC, Mazi\u00e8re JC, Chauffert B, et al. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. Int J Cancer. 2013;133(7):1732\u201342.","journal-title":"Int J Cancer"},{"issue":"2","key":"2208_CR43","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.canlet.2013.12.028","volume":"346","author":"A Galmiche","year":"2014","unstructured":"Galmiche A, Chauffert B, Barbare J-C. New biological perspectives for the improvement of the efficacy of sorafenib in hepatocellular carcinoma. Cancer Lett. 2014;346(2):159\u201362.","journal-title":"Cancer Lett"},{"issue":"2","key":"2208_CR44","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/hep.28574","volume":"64","author":"X Sun","year":"2016","unstructured":"Sun X, Niu X, Chen R, He W, Chen D, Kang R, et al. Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis. Hepatology. 2016;64(2):488\u2013500.","journal-title":"Hepatology"},{"issue":"4","key":"2208_CR45","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1038\/s41418-020-00644-4","volume":"28","author":"K Wang","year":"2021","unstructured":"Wang K, Zhang Z, Tsai H-i, Liu Y, Gao J, Wang M, et al. Branched-chain amino acid aminotransferase 2 regulates ferroptotic cell death in cancer cells. Cell Death Differ. 2021;28(4):1222\u201336.","journal-title":"Cell Death Differ"},{"issue":"1","key":"2208_CR46","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nchembio.2239","volume":"13","author":"S Doll","year":"2017","unstructured":"Doll S, Proneth B, Tyurina YY, Panzilius E, Kobayashi S, Ingold I, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2017;13(1):91\u20138.","journal-title":"Nat Chem Biol"},{"issue":"1","key":"2208_CR47","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41401-020-0439-x","volume":"42","author":"J Feng","year":"2021","unstructured":"Feng J, Lu P-z, Zhu G-z, Hooi SC, Wu Y, Huang X-w, et al. ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma. Acta Pharmacol Sin. 2021;42(1):160\u201370.","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"2208_CR48","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/jcb.27456","volume":"120","author":"YS Lee","year":"2019","unstructured":"Lee YS, Lee DH, Jeong SY, Park SH, Oh SC, Park YS, et al. Ferroptosis-inducing agents enhance TRAIL-induced apoptosis through upregulation of death receptor 5. J Cell Biochem. 2019;120(1):928\u201339.","journal-title":"J Cell Biochem"},{"issue":"7","key":"2208_CR49","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1158\/1541-7786.MCR-18-0055","volume":"16","author":"Y-S Lee","year":"2018","unstructured":"Lee Y-S, Lee D-H, Choudry HA, Bartlett DL, Lee YJ. Ferroptosis-induced endoplasmic reticulum stress: cross-talk between ferroptosis and apoptosis. Mol Cancer Res. 2018;16(7):1073\u20136.","journal-title":"Mol Cancer Res"},{"issue":"9","key":"2208_CR50","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s10495-020-01627-z","volume":"25","author":"Y-S Lee","year":"2020","unstructured":"Lee Y-S, Kalimuthu K, Park YS, Luo X, Choudry MHA, Bartlett DL, et al. BAX-dependent mitochondrial pathway mediates the crosstalk between ferroptosis and apoptosis. Apoptosis. 2020;25(9):625\u201331.","journal-title":"Apoptosis"},{"issue":"4","key":"2208_CR51","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S1386-6346(03)00268-7","volume":"27","author":"I Ozaki","year":"2003","unstructured":"Ozaki I, Mizuta T, Zhao G, Zhang H, Yoshimura T, Kawazoe S, et al. Induction of multiple matrix metalloproteinase genes in human hepatocellular carcinoma by hepatocyte growth factor via a transcription factor Ets-1. Hepatol Res. 2003;27(4):289\u2013301.","journal-title":"Hepatol Res"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-021-02208-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-021-02208-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-021-02208-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T07:15:46Z","timestamp":1676099746000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-021-02208-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,3]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2208"],"URL":"https:\/\/doi.org\/10.1186\/s13046-021-02208-x","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,3]]},"assertion":[{"value":"26 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The tissue microarray chips were purchased from Outdo Biotech, Ltd. (Shanghai, China), with the approval of the Institutional Review Board. All animal protocols were approved by the Committee on the Use of Live Animals in the Teaching and Research of The University of Hong Kong.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}